Last reviewed · How we verify
NCT05198869
SpotLight-19 Research & Development Study
NA trial testing Spectral scan in Screening in 12,500 participants. Status unknown.
30 April 2022
Quick facts
| Lead sponsor | Ottawa Hospital Research Institute |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 12,500 |
| Start date | 29 December 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 31 July 2022 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Spectral scan
Conditions studied
- Screening — all drugs for Screening →
Sponsor
Ottawa Hospital Research Institute
Who can join
3 and older, any sex, with Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, we will use the SpotLight-19 device in patients presenting to a coronavirus disease (COVID-19) Assessment Centre for polymerase chain reaction (PCR) testing. Consenting patients will undergo a Spotlight-19 scan. We will link the scan to PCR results, age, vaccination status, and COVID-19 symptoms in order to calibrate the SpotLight-19 prediction algorithm of a state of COVID-19 infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05198869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Screening
Currently open trials in the same condition.
- NCT07277686 — AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population · recruiting
- NCT07125365 — UK Islet Autoantibody Registry · recruiting
- NCT06792188 — Smartwatch-Based AI Model for OSA Prediction (SWOSA) · recruiting
- NCT06870435 — Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcin · NA · recruiting
- NCT06799793 — Artificial Intelligence-based Screening Models for Prevention and Early Detection of Colorectal Cancer · NA · recruiting
Other Ottawa Hospital Research Institute trials
Trials by the same sponsor.
- NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
- NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
- NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
- NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
- NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05198869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
- Last refreshed: 20 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05198869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing